U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

  1. Home
  2. Drugs
  3. Development & Approval Process | Drugs
  4. Drug Development Tool (DDT) Qualification Programs
  5. Clinical Outcome Assessment (COA) Qualification Program
  6. DDT COA #000056: Varicose Vein Symptom Questionnaire (VVSymQ)
  1. Clinical Outcome Assessment (COA) Qualification Program

DDT COA #000056: Varicose Vein Symptom Questionnaire (VVSymQ)

Clinical Outcome Assessments (COA) Qualification Submissions
Office of Cardiology, Hematology, Endocrinology, and Nephrology (OCHEN)
Division of Cardiovascular and Nephrology (DCN)

DDT COA Number
DDT COA #000056

Instrument Name
Varicose Vein Symptom Questionnaire (VVSymQ)

Disease/Condition
Varicose Veins

Concept of Interest
Varicose vein symptoms

Context of Use
Patients with superficial venous incompetence

COA Type
PRO

Qualification Stage
In legacy process*

Requestor(s)
BTG International, Inc

Contact(s)
Simon Leppard

Date Accepted into CDER’s COA Qualification Program
May 13, 2014

 

*Under review prior to the passage of the 21st Century Cures Act

Back to Top